TSHA vs AVLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TSHA · Taysha Gene Therapies$3.72 ▼ 1.33%
AVLN · Avalyn Pharma$28.40 ▼ 1.05%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TSHA -41.8%
- AVLN -3.7%
Head to head
| Metric | TSHA | AVLN |
|---|---|---|
| Price | $3.72 | $28.40 |
| Change today | ▼ 1.33% | ▼ 1.05% |
| Market cap | $1.21B | $1.26B |
| Return, 3 months | -37.7% | -24.6% |
| Return, year to date | -32.4% | – |
| Return, 1 year | -11.2% | – |
| P/E (TTM) | – | – |
| P/B | 3.4 | 3.4 |
| P/E percentile vs own 5y | 22nd | 74th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | – |
| Net profit growth (YoY) | -73.5% | -43.3% |
| Gross margin | – | – |
| Operating margin | -2,854.9% | – |
| Net margin | -2,728.0% | – |
| Return on equity | -47.1% | -25.9% |
| Analyst target vs. price | +285.2% | +111.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 35 | 51 |
| 30-day volatility | 74.4% | 62.3% |
| Max drawdown, 1 year | -49.7% | -40.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVLN is the largest of the group by market value.
- AVLN has been the calmest stock over the last 30 days.